SCHEMBL7349359

SCHEMBL7349359

CCOC(=O)c1cccc2[nH]nc(Br)c12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.51
TSHR P16473 1/20 0.50
ALDH1A1 P00352 4/20 0.44
HSD17B10 Q99714 3/20 0.44
CYP1A2 P05177 1/20 0.43
CLEC4M Q9H2X3 1/20 0.42
CDC25B P30305 1/20 0.42
KMT2A Q03164 2/20 0.41
MEN1 O00255 1/20 0.41
POLB P06746 1/20 0.41
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA7 P43166 1/20 0.41
CA9 Q16790 1/20 0.41
CA14 Q9ULX7 1/20 0.41
LMNA P02545 1/20 0.40
PARP1 P09874 1/20 0.40
CDK1 P06493 1/20 0.40
CDK2 P24941 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5503774 0.84 KDM4E (0.52) KDM4ETSHRALDH1A1HSD17B10CYP1A2
SCHEMBL30424394 0.84 KDM4E (0.48) KDM4ETSHRALDH1A1HSD17B10KMT2A
SCHEMBL1135530 0.84 KDM4E (0.48) KDM4ETSHRALDH1A1HSD17B10KMT2A
SCHEMBL5971733 0.80 HPGDS (0.55) KDM4ETSHRALDH1A1HSD17B10KMT2A
SCHEMBL5583821 0.79 PBRM1 (0.38) KDM4ETSHRALDH1A1HSD17B10CYP1A2
SCHEMBL6009595 0.77 TSHR (0.61) KDM4ETSHRALDH1A1HSD17B10CYP1A2
SCHEMBL7348395 0.77 KDM4E (0.48) KDM4ETSHRALDH1A1HSD17B10CYP1A2
SCHEMBL25222245 0.77 NUDT1 (0.54) KDM4ETSHRALDH1A1KMT2AMEN1
SCHEMBL30989297 0.77 NUDT1 (0.54) KDM4ETSHRALDH1A1KMT2AMEN1
SCHEMBL7348330 0.76 KDM4E (0.47) KDM4ETSHRALDH1A1HSD17B10CDC25B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6214834-B1 ANGIOGENESIS INHIBITORS; ANTIINFLAMMATORY AGENTS; ANTICANCER AGENTS DUPONT PHARMACEUTICALS COMPANY 2001-04-10 US disclosed
WO-1998043962-A1 HETEROCYCLIC INTEGRIN INHIBITOR PRODRUGS DU PONT PHARMACEUTICALS COMPANY (US) 1998-10-08 WO disclosed
US-5760028-A TREATING CANCER METASTASIS, DIABETIC RETINOPATHY, NEOVASCULAR GLAUCOMA, THROMBOSIS, RESTENOSIS, OSTEOPOROSIS, MACULAR DEGENERATION THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) 1998-06-02 US disclosed